Smellprints in lung Cancer; the role of ENose in diagnosis and Treatment (SCENT): part 1. Differences in smellprints between patients with lung cancer and breast cancer

Smellprints in lung Cancer; the role of ENose in diagnosis and Treatment (SCENT): part 1. Differences in smellprints between patients with lung cancer and breast cancer - eNose in lung cancer/SCENT study, part 1

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON35264

Enrollment

100

Registered

2008-12-15

Start date

2009-01-02

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer lung cancer or bronchial carcinoma

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. all women (18-80 yr) suspected of having breast cancer, referred to the OPD specialised in the diagnostic work-up of breast abnormalities in our hospital will be asked to participate (intention-to-diagnose). The first 25 patients with histologically confirmed breast cancer will be included in the analysis. 2. all patients (18-80 yr) suspected of having lung cancer, referred to the pulmonary OPD in our hospital will be asked to participate (intention-to-diagnose). The first 25 patients with histologically confirmed non-small cell lung cancer will be included in the analysis. 3. 25 women without breast cancer, matched with breast cancer patients above for age and smoking history, will be randomly selected from the intention-to-diagnose cohort. 4. 25 healthy controls, matched with the lung cancer patients above for sex, age, and smoking history, will be recruited from visitors and personel of our hospital, of course on voluntary base.

Exclusion criteria

Exclusion criteria: other pulmonary disease. diabetes mellitus. documented hypercholesterolemia. malignancy in past. Significant cardiovascular pathology. Presence of paradontitis, history of upper or lower respiratory tract infection in the past 4 weeks. Pregnancy, eating (including chewing gum), drinking, smoking

Design outcomes

Primary

Measure	Time frame
The primary outcome parameter is the difference in smellprints provided by eNose between patients with lung cancer and breast cancer.	—

Secondary

Measure	Time frame
The secondary outcomes are: - the difference in smellprints between women with and without breast cancer - the difference in smellprints between patients with non-small cell lung cancer and healthy controls - the difference in smellprints between patients before and twice after resection of the lung tumour (at 1 and 6 weeks post-resection)	—

Countries

Netherlands

Outcome results